8 completed, 1 unknown. 9 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 8, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
Follow PCV13: new trials by email Literature Review of PCV13 trials Research Report on PCV13
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033) V114, PCV13 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 694 | 2020-07-01 | 2023-07-28 |
| Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024) V114, Prevnar 13® - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 606 | 2019-06-25 | 2023-01-13 |
| CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study PCV13 - Invasive Pneumococcal Disease, Protection Against, Streptococcus Pneumoniae Infection | Phase 2 / Phase 3 | Completed | University of British Columbia | 248 | 2018-08-23 | 2024-03-04 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY) V114, Prevnar 13™, PNEUMOVAX™23 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1515 | 2018-07-16 | 2021-01-15 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) V114, Prevnar 13™, PNEUMOVAX™23 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 652 | 2018-06-22 | 2021-11-02 |
| Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older HZ/su vaccine GSK1437173A, Prevenar13 - Herpes Zoster | Phase 3 | Completed | GlaxoSmithKline | 913 | 2018-04-12 | 2022-01-11 |
| Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers MenACYW conjugate vaccine, MMR, Varicella - Meningitis, Meningococcal | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1183 | 2016-11-07 | 2022-04-05 |
| Protecting From Pneumococcus in Early Life (The PROPEL Trial) 13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid, placebo 0.9% sodium chloride plus tetanus toxoid, tetanus toxoid - Pneumonia | Phase 3 | Unknown | London School of Hygiene and Tropical Medicine | 600 | 2016-03-11 | 2020-10-23 |
| Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam PCV10, PCV13 - Pneumococcal Vaccines | Phase 2 / Phase 3 | Completed | Murdoch Childrens Research Institute | 1400 | 2013-09-30 | 2022-09-14 |
Pneumococcal Infections (5) · Herpes Zoster (1) · Meningitis (1) · Meningitis, Meningococcal (1) · Meningococcal Infections (1) · Pneumonia (1)
Merck Sharp & Dohme LLC (4) · GlaxoSmithKline (1) · London School of Hygiene and Tropical Medicine (1) · Murdoch Childrens Research Institute (1) · Sanofi Pasteur, a Sanofi Company (1) · University of British Columbia (1)
Canada (3) · Russia (3) · United States (3) · Poland (2) · South Korea (2) · Thailand (2) · Australia (1) · Chile (1) · Estonia (1) · Finland (1) · Germany (1) · Japan (1) · Malaysia (1) · Mexico (1) · New Zealand (1)
Ed Clarke, MB (1) · Edward K Mulholland, MBBS, FRACP (1) · Manish Sadarangani, MD (1)
PMID 29884695, PMID 30975525, PMID 33745731, PMID 33814028, PMID 34171233, PMID 34489128, PMID 34963639, PMID 35146039, PMID 36150974, PMID 36785850, PMID 37344262, PMID 40537903, PMID 41442837
2017 (3), 2018 (1), 2019 (1)